Intelligence Report · ~12 min read

Eli Lilly Intelligence Report

Generated from 75 signals · 12 evidence sources

Type

Company Intelligence Report

Generated

Jul 22, 2026

Confidence

Moderate Confidence · 68%

Evidence

289 items

Sources

105

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Eli Lilly maintains an active intelligence profile across Oncology, mTOR Inhibitor, Diabetes, GLP-1, Hematology. 75 signals are linked with 11 investigate-priority items requiring leadership attention. Competitive pressure is high with high portfolio impact. Evidence coverage stands at 68% across 12 tracked sources. Highest-priority development: FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis. Portfolio development. FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis is an owned Eli Lilly portfolio development in Oncology · mTOR Inhibitor.

Key Developments

Material intelligence events ranked by strategic relevance.

investigateJun 16, 2026
Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial
Cardiovascular · Gene Editing · opportunity score 327
View detail
investigateJun 17, 2026
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Infectious Disease · Respiratory Syncytial Virus (RSV) · opportunity score 324
View detail
investigateJun 27, 2026
Lilly's Jaypirca recommended for EU approval in CLL across all therapy lines
Hematology · CLL · opportunity score 321
View detail
investigateJul 21, 2026
Lilly to acquire Ajax Therapeutics for myelofibrosis and polycythemia vera
Hematology · JAK2 Inhibition · opportunity score 320
View detail
investigateJul 21, 2026
Lilly to acquire Kelonia Therapeutics for in vivo CAR-T cell therapy advancement
Oncology · CAR-T · opportunity score 320
View detail
investigateJun 16, 2026
Lilly's Retevmo shows 83% reduction in disease recurrence for early-stage RET fusion-positive lung cancer
Oncology · RET fusion-positive lung cancer · opportunity score 320
View detail
investigateJun 15, 2026
Lilly's Jaypirca shows 45% reduction in disease progression risk in CLL/SLL
Hematology · CLL/SLL · opportunity score 320
View detail
investigateJun 14, 2026
Lilly presents promising Phase 1 data for first-in-class type II JAK2 inhibitor in myelofibrosis
Hematology · Myelofibrosis · opportunity score 320
View detail
investigateJul 17, 2026
Lilly to acquire AtaiBeckley to enhance treatment-resistant depression therapies
Neuroscience · Depression · opportunity score 319
View detail
investigateJun 16, 2026
Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide
Obesity · GLP-1/GIP Receptor Agonist and Amylin Analog · opportunity score 319
View detail
investigateJun 16, 2026
Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide
Obesity · GLP-1/GIP Receptor Agonist and Amylin Analog · opportunity score 319
View detail
portfolio
FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis
FDA approval
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 23952 with buyer quality 10 (Enterprise). Competitive pressure: High. Portfolio impact: High. 11 investigate-priority signals warrant near-term portfolio review. Competitiva linkage surfaces 2 competitive findings requiring monitoring.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

Lilly (named in signal competitive context)
Moderate Confidence · 72%
Elevated competitive pressure
Source: FDA, Competitiva
View evidence
Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026
High Confidence · 95%
Potential competitive pressure
Source: Lilly, Competitiva
View evidence
FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis
Low Confidence · 0%
FDA approval
Source: Humanexa Signals, FDA, Portfolio
View evidence
Novartis initiates pediatric study for asciminib in Chronic Myeloid Leukemia
Low Confidence · 0%
FDA approval
Source: Lilly, ClinicalTrials.gov, Portfolio
View evidence
AstraZeneca's Elecoglipron Phase III Trials Target Obesity and T2DM
Low Confidence · 0%
FDA approval
Source: Humanexa Signals, ClinicalTrials.gov, Portfolio
View evidence
Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease
Low Confidence · 0%
Phase II success
Source: Lilly, ClinicalTrials.gov, Portfolio
View evidence
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Low Confidence · 0%
FDA approval
Source: Lilly, Merck, Portfolio
View evidence
Hoffmann-La Roche's Enicepatide Trial Targets Obesity and Type 2 Diabetes
Low Confidence · 0%
Phase III success
Source: Lilly, ClinicalTrials.gov, Portfolio
View evidence
Merck's MK-1403 Trial Targets Type 2 Diabetes and hsCRP Levels
Low Confidence · 0%
Phase III success
Source: Lilly, ClinicalTrials.gov, Portfolio
View evidence
Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management
Low Confidence · 0%
Phase II success
Source: Humanexa Signals, Pfizer, Portfolio
View evidence
Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate
Low Confidence · 0%
Portfolio development
Source: Lilly, Merck, Portfolio
View evidence
Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate
Low Confidence · 0%
Portfolio development
Source: Humanexa Signals, Merck, Portfolio
View evidence
Novartis initiates trial for inclisiran in acute coronary syndromes
Low Confidence · 0%
Portfolio development
Source: Lilly, ClinicalTrials.gov, Portfolio
View evidence
Study on Host-Pathogen Interaction with Staphylococcus aureus Using Lymphoid Organoids
Low Confidence · 0%
Portfolio development
Source: Lilly, ClinicalTrials.gov, Portfolio
View evidence
RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer
Low Confidence · 0%
Portfolio development
Source: Lilly, ClinicalTrials.gov, Portfolio
View evidence
Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026
Low Confidence · 0%
Phase III success
Source: Lilly, Roche, Portfolio
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

FDA Approves Supplemental Application for IBRANCE (Palbociclib)
Oncology · CDK4/6 Inhibitor
Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial
Cardiovascular · Gene Editing
Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease
Neurology · Alzheimer's Disease
Lilly presents new Alzheimer's diagnostic and therapeutic data at AAIC 2026
Neurology · Alzheimer's Disease
Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments
Neurology · Sleep-Wake Disorders
FDA Approves Supplemental Application for Retevmo (Selpercatinib)
Oncology · RET Inhibitor
OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients
Infectious Disease · COVID-19
Phase III Trial of Giredestrant vs Endocrine Therapy in ER+ HER2- Early Breast Cancer
Oncology · Breast Cancer

Executive Summary

Key Developments

Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants

Lilly's Jaypirca recommended for EU approval in CLL across all therapy lines

Lilly to acquire Ajax Therapeutics for myelofibrosis and polycythemia vera

Lilly to acquire Kelonia Therapeutics for in vivo CAR-T cell therapy advancement

Lilly's Retevmo shows 83% reduction in disease recurrence for early-stage RET fusion-positive lung cancer

Lilly's Jaypirca shows 45% reduction in disease progression risk in CLL/SLL

Lilly presents promising Phase 1 data for first-in-class type II JAK2 inhibitor in myelofibrosis

Lilly to acquire AtaiBeckley to enhance treatment-resistant depression therapies

Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide

FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis

Strategic Implications

Supporting Evidence

Lilly (named in signal competitive context)

Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026

FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis

Novartis initiates pediatric study for asciminib in Chronic Myeloid Leukemia

AstraZeneca's Elecoglipron Phase III Trials Target Obesity and T2DM

Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants

Hoffmann-La Roche's Enicepatide Trial Targets Obesity and Type 2 Diabetes

Merck's MK-1403 Trial Targets Type 2 Diabetes and hsCRP Levels

Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management

Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate

Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate

Novartis initiates trial for inclisiran in acute coronary syndromes

Study on Host-Pathogen Interaction with Staphylococcus aureus Using Lymphoid Organoids

RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Related Intelligence

Signals